Delivery of endostatin in experimental cancer therapy

Dag R. Sorensen, Tracy Ann Read

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Endostatin, the 20kDa C-terminal fragment of collagen XVIII, has been shown to be an effective inhibitor of tumour angiogenesis and growth in different experimental systems and is currently in Phase II/III clinical trials. One challenging aspect of anti-angiogenic treatment is the mode of delivery of the active compound. In this paper we review some of the basic knowledge of endostatin and look specifically into the different possible ways in which endostatin may be administered.

Original languageEnglish (US)
Pages (from-to)265-274
Number of pages10
JournalInternational Journal of Experimental Pathology
Issue number6
StatePublished - Dec 2002
Externally publishedYes


  • Cancer
  • Delivery
  • Endostatin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Delivery of endostatin in experimental cancer therapy'. Together they form a unique fingerprint.

Cite this